Key statistics
As of last trade, Candel Therapeutics Inc (CADL:NMQ) traded at 5.64, 32.59% above the 52 week low of 4.25 set on Apr 09, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 5.54 |
|---|---|
| High | 5.91 |
| Low | 5.50 |
| Bid | 5.63 |
| Offer | 5.66 |
| Previous close | 5.53 |
| Average volume | 556.15k |
|---|---|
| Shares outstanding | 54.90m |
| Free float | 45.70m |
| P/E (TTM) | -- |
| Market cap | 303.59m USD |
| EPS (TTM) | -0.5591 USD |
Data delayed at least 15 minutes, as of Feb 12 2026 17:38 GMT.
More ▼
- Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit
- Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Candel Therapeutics to Host Virtual R&D Event on December 5, 2025
- Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
- Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors
- Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London
- Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board
- Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.
- Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine
- Candel Therapeutics to Present at the SITC 2025 Annual Meeting
More ▼
